ADVAIR 250 DISKUS POWDER

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

SALMETEROL (SALMETEROL XINAFOATE); FLUTICASONE PROPIONATE

Commercializzato da:

GLAXOSMITHKLINE INC

Codice ATC:

R03AK06

INN (Nome Internazionale):

SALMETEROL AND FLUTICASONE

Dosaggio:

50MCG; 250MCG

Forma farmaceutica:

POWDER

Composizione:

SALMETEROL (SALMETEROL XINAFOATE) 50MCG; FLUTICASONE PROPIONATE 250MCG

Via di somministrazione:

INHALATION

Confezione:

28,60 DOSES

Tipo di ricetta:

Prescription

Area terapeutica:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0238341002; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

1999-09-03

Scheda tecnica

_ _
_ _
_Page 1 of 70_
PR
ADVAIR DISKUS
fluticasone propionate and salmeterol inhalation powder USP
Pr
ADVAIR DISKUS _100_
100 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR DISKUS _250_
250 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR DISKUS _500_
500 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
PR
ADVAIR
fluticasone propionate and salmeterol pressurised inhalation,
suspension BP
Pr
ADVAIR _125_
125 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR _250_
250 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate
salt)
Corticosteroid and Bronchodilator for Oral Inhalation
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
June 17, 2020
Submission Control No: 237271
_© 2020 GSK group of companies or its licensor_
Trademarks are owned by or licensed to the GSK group of companies.
_ _
_ _
_Page 2 of 70_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
3
SUMMARY
PRODUCT
INFORMATION
...............................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.....................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS
AND
PRECAUTIONS
........................................................................................................
4
ADVERSE
REACTIONS
........................................................................................................................
15
DRUG
INTERACTIONS
........................................................................................................................
24
DOSAGE
AND
ADMINISTRATION..........................................................................